Facebook Users

RIGL Rigel Pharmaceuticals, Inc., featured news, full reports, and detailed RIGL.O charts.

Rigel Pharmaceuticals, Inc. (RIGL) Wrap Up:

Rigel Pharmaceuticals, Inc. was incorporated in Delaware in June 1996, and is based in South San Francisco. Rigel is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory/autoimmune diseases, cancer and viral diseases. Our goal is to file one new investigative new drug, or IND, application in a significant indication each year. We have achieved this goal each year beginning in 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Our productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have internal product development programs in inflammatory/autoimmune diseases, such as rheumatoid arthritis and thrombocytopenia, and cancer, as well as partnered product development programs relating to asthma and cancer.  ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f07%2f0001047469-08-002350.html#FIS_BUSINESS"   
www.rigel.com
181 Employees
Founded in 1996

Rigel Pharmaceuticals, Inc. (RIGL:NASDAQ)

LAST $7.40 USD
CHANGE TODAY +0.14 1.93%
VOLUME 552.2K
As of 4:00 PM 11/6/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).

Snapshot of Rigel Pharmaceuticals, Inc. (RIGL)

OPEN
$7.19
PREVIOUS CLOSE
$7.26
DAY HIGH
$7.56
DAY LOW
$7.17
52 WEEK HIGH
07/21/09 - $14.75
52 WEEK LOW
03/6/09 - $4.19
MARKET CAP
383.5M
AVERAGE VOLUME 3 mo
932.1K
DILUTED EPS TTM
$-3.24
SHARES OUTSTANDING
51.8M
RIGL Does Not Pay Dividends
P/E TTM
NM
K = Thousands  M = Millions  B = Billions

related news

Marcial: Pharma Firms May Vie for Vertex

Telaprevir is a potential blockbuster drug for treating hepatitis C, with a multibillion-dollar market. Vertex could get FDA approval for it next year

Stocks End Modestly Lower

Investors Thursday weighed reports showing a jump in the Philadelphia Fed index, a decline in jobless claims, and a rise in housing starts

related news

*Rigel 3Q loss narrows on lower costs

RIGL Details

Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Its product development portfolio includes R788, which is in Phase 2b clinical trial for the treatment of rheumatoid arthritis (RA); a Phase 2 clinical trial for the treatment of immune thrombocytopenia purpura, B-cell lymphoma, and T-cell lymphoma; and a preclinical stage for the treatment of lupus. The company’s products also include R348, which is in Phase 1 clinical trial for Psoriasis; R763, which is in Phase 1 clinical trial in the area of oncology; and R343, a Phase 1 clinical trial product for asthma. It has collaboration agreements with Janssen Pharmaceutica N.V.; Pfizer, Inc.; Novartis Pharma AG; Daiichi Pharmaceuticals Co., Ltd.; Merck & Co., Inc.; and Merck Serono. The company was founded in 1996 and is based in South San Francisco, California.

RIGL Top Compensated Officers

Mr. James M. Gower
Chairman of the Board, Chief Executive Office...
Age: 60
Total Annual Compensation: $600.0K
Dr. Donald G. Payan M.D.
Co-Founder, President of Discovery & Research...
Age: 60
Total Annual Compensation: $483.0K
Mr. Ryan D. Maynard
Chief Financial Officer, Principal Accounting...
Age: 39
Total Annual Compensation: $300.0K
Mr. Raul R. Rodriguez
Chief Operating Officer and Executive Vice Pr...
Age: 48
Total Annual Compensation: $430.0K
Dr. Elliott B. Grossbard M.D.
Chief Medical Officer and Executive Vice Pres...
Age: 61
Total Annual Compensation: $450.0K

Executives, Board Directors

Compensation as of Fiscal Year 2008.

Key developments for Rigel Pharmaceuticals, Inc. (RIGL)

Rigel Pharmaceuticals Inc. Reports Unaudited Financial Results for the Third Quarter and Nine Months Ended September 30, 2009

Rigel Pharmaceuticals Inc. reported unaudited financial results for the third quarter and nine months ended September 30, 2009. For the third quarter of 2009, the company reported a net loss of $26.7 million, or $0.70 per share, compared to a net loss of $37.7 million, or $1.03 per share, in the third quarter of 2008. Loss from operations was $26.7 million against $38.7 million a year ago. Loss before income taxes was $26.7 million against $37.7 million a year ago. For the nine months ended September 30, 2009, the company reported a net loss of $86.5 million, or $2.32 per share, compared to a net loss of $99.0 million in the first nine months of 2008, or $2.76 per share. Loss from operations was $86.9 million against $102.7 million a year ago. Loss before income taxes was $86.6 million against $98.98 million a year ago.

Rigel Pharmaceuticals, Inc. - Conference Presentation Call

Rigel Pharmaceuticals, Inc. - Conference Presentation Calls

Rigel Pharmaceuticals, Inc. - Conference Presentation Call

Rigel Pharmaceuticals, Inc. - Conference Presentation Calls

otc, otcbb, pinksheet, RIGL, ob Rigel Pharmaceuticals, Inc.

RIGL Competitors

Company Last Change
Arena Pharmaceuticals Inc $3.49 USD -0.03
Idenix Pharmaceuticals Inc $1.92 USD -0.04
MVIR BTA B, Medivir AB kr68.00 SEK 0.00
Pharmasset Inc $21.10 USD +1.30
Evotec Aktiengesellschaft $6.63 USD +0.13
Market data is delayed at least 20 minutes.

Industry Analysis

Valuation RIGL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

RIGL

 | 

RIGL transactions

Type
Date
Target
No transactions in the last 6 months.

More Recent News About Rigel Pharmaceuticals, Inc.

  • Fundamental and Technical Research for LINE, PCAR, RIGL, INTC, NTAP and HERO Posted on BenchmarkJournal.com Today 

    Benchmark Journal brings independent company and sector research together, utilizing top financial advisors and investment tactics to...

    Market Wire, 11/02/09 · More from publication

Would you like to leave a comment about Rigel Pharmaceuticals, Inc. (RIGL)?

Besides Rigel Pharmaceuticals, Inc. there is more great information available at Realpennies.com